Ever since human induced pluripotent stem cells were first derived in 2007, scientists have wondered whether they were functionally equivalent to embryonic stem cells, which are sourced in early stage embryos.
Both cell types have the ability to differentiate into any cell in the body, but their origins — in embryonic and adult tissue — suggest that they are not identical.
Although both cell types have great potential in basic biological research and in cell- and tissue-replacement therapy, the newer form, called IPS cells, have two advantages. They face less ethical constraint, as they do not require embryos. And they could